Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| VU-VICC-GYN-0648 | |||
| VU-VICC-IRB-060680 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute (NCI) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
RATIONALE: Measuring the amount of prostaglandin metabolite in urine samples and studying tissue samples in the laboratory from patients with ovarian cancer may help doctors identify and learn more about biomarkers related to ovarian cancer and may help the study of cancer in the future.
PURPOSE: This laboratory study is measuring the amount of prostaglandin metabolite in urine samples from patients with ovarian cancer.
OBJECTIVES:
OUTLINE: This is a pilot study.
Patients submit 24-hour urine specimens prior to surgery for evaluation of urinary levels of prostaglandin E_2 metabolite (PGE-M).
Patients also undergo assessment of tissue obtained at the time of surgery, including ovarian tumor tissue, normal surface ovarian epithelium tissue (if available), and fixed tissue embedded in a paraffin block. Tissue samples are analyzed by western blot and IHC for cyclooxygenase-1 and cyclooxygenase-2 expression.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Known or suspected ovarian cancer | Women who have a diagnosis of ovarian cancer or who are suspected of having ovarian cancer |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| protein expression analysis | Genetic | protein expression analysis |
|
| Measure | Description | Time Frame |
|---|---|---|
| Prostaglandin E2 metabolite (PGE-M) levels in 24-hour urine samples | Patients will be collect their urine for 24 hours before they undergo any surgery or chemotherapy. Researchers will measure the amount of PGE-M in the urine. | Pre-surgical or chemotherapeutic treatment, over a 24-hour duration |
| Measure | Description | Time Frame |
|---|---|---|
| COX-1 and COX-2 expression in ovarian tumor tissue and non-malignant tissue | COX-1 and COX-2 expression will be measured in samples of patients' malignant ovarian samples and matched non-malignant samples (the latter if available). | Day of surgery |
| Correlation of urine PGE-M levels with tissue COX-1 and COX-2 levels |
Not provided
Inclusion Criteria:
Exclusion Criteria:
PRIOR CONCURRENT THERAPY:
Not provided
Not provided
Not provided
Women with known or suspected ovarian cancer who are greater than 17 years in age.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Marta Crispens, MD | Vanderbilt-Ingram Cancer Center | Principal Investigator |
Not provided
Not provided
| ID | Term |
|---|---|
| D010051 | Ovarian Neoplasms |
| D000077216 | Carcinoma, Ovarian Epithelial |
| ID | Term |
|---|---|
| D004701 | Endocrine Gland Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D010049 | Ovarian Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C060526 | 7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid |
| D007150 | Immunohistochemistry |
| ID | Term |
|---|---|
| D006651 | Histocytochemistry |
| D003584 | Cytological Techniques |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
Not provided
Not provided
Not provided
Not provided
Not provided
| immunohistochemistry | Other | immunohistochemical staining of tumor tissue to measure COX-1 and COX-2 levels |
|
|
Patients' levels of urine PGE-M will be compared and contrasted with their levels of COX-1 and COX-2 in ovarian tumor tissue |
| After patients' surgery |
| D000291 |
| Adnexal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D005833 | Genital Neoplasms, Female |
| D014565 | Urogenital Neoplasms |
| D000091662 | Genital Diseases |
| D004700 | Endocrine System Diseases |
| D006058 | Gonadal Disorders |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D003933 | Diagnosis |
| D006652 | Histological Techniques |
| D008919 | Investigative Techniques |
| D007158 | Immunologic Techniques |